Immunovant, Inc. (IMVT) Covered Calls

Immunovant, Inc. is a clinical-stage immunology company developing targeted therapies for autoimmune diseases. It focuses on inhibiting the neonatal Fc receptor (FcRn) to reduce pathogenic IgG antibodies. Its lead candidate, IMVT-1402, is designed for subcutaneous delivery to treat conditions like Graves’ disease and myasthenia gravis.

You can sell covered calls on Immunovant, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for IMVT (prices last updated Tue 4:16 PM ET):

Immunovant, Inc. (IMVT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
27.39 +0.19 24.90 27.85 812K - 5.5
Covered Calls For Immunovant, Inc. (IMVT)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 27 1.85 26.00 3.8% 55.5%
Apr 17 27 2.75 25.10 7.6% 52.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Immunovant, Inc. (NASDAQ: IMVT), headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for people living with autoimmune diseases. The company is a leader in anti-FcRn technology, which targets the neonatal Fc receptor (FcRn). By blocking this receptor, Immunovant’s therapies accelerate the degradation of Immunoglobulin G (IgG) antibodies, which are often the drivers of autoimmune inflammation. The company’s strategy focuses on "pipeline-in-a-product" development, targeting multiple large-market indications across neurology, endocrinology, and rheumatology where high unmet medical needs persist.

Core Business and Products

  1. IMVT-1402: The company’s lead asset, a next-generation fully human monoclonal antibody designed to inhibit FcRn. Unlike earlier candidates, IMVT-1402 aims to provide deep IgG reduction without significantly impacting albumin or LDL cholesterol levels, potentially allowing for chronic, high-dose administration.
  2. Batoclimab: A first-generation anti-FcRn antibody currently in Phase 3 trials for Thyroid Eye Disease (TED). While the company is prioritizing IMVT-1402 for many future indications, batoclimab serves as a critical clinical proof-of-concept for the FcRn mechanism in complex autoimmune conditions.
  3. Subcutaneous Delivery Focus: A key differentiator for Immunovant is the focus on simple, subcutaneous self-administration. This delivery method is designed to offer patients a more convenient alternative to the intravenous infusions typically required for traditional autoimmune treatments.

Competitive Landscape

Immunovant operates in the highly competitive FcRn inhibitor market. Its primary rival is argenx SE, which has already commercialized Vyvgart for myasthenia gravis. The company also faces competition from Johnson & Johnson, which is developing nipocalimab, and UCB with its approved drug Rystiggo. Additionally, it competes for capital and market share with other immunology-focused firms like Roivant Sciences (its majority shareholder) and Regeneron. Immunovant’s competitive edge lies in the potentially superior safety and lipid profile of IMVT-1402 compared to first-generation inhibitors.

Strategic Outlook and Innovation

Immunovant’s 2026 strategy is centered on several major clinical readouts that could validate its next-generation platform. In the first half of 2026, the company expects topline data from its two Phase 3 trials of batoclimab in Thyroid Eye Disease. Simultaneously, the potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis and a proof-of-concept study in cutaneous lupus erythematosus are on track for results in the second half of 2026. These milestones are critical for positioning IMVT-1402 as a multi-indication "best-in-class" therapy across the autoimmune landscape.

Financially, the company is well-capitalized following a $550 million financing round in late 2025, extending its cash runway into 2028. This allows Immunovant to aggressively pursue ten total indications for IMVT-1402, including Graves’ disease and myasthenia gravis, where pivotal data is expected in 2027. Innovation efforts are also directed at expanding the "Propel" and "Forward" trial frameworks to include AI-driven patient screening. By leveraging large datasets to identify patients most likely to respond to FcRn blockade, Immunovant aims to optimize its clinical success rates and shorten the path to commercialization for its entire pipeline.